Skip to main content
Fig. 4 | BMC Medicine

Fig. 4

From: Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy for locally advanced rectal cancer: 3-year survival from a phase 2 study

Fig. 4

Subgroup analysis of 3-year overall survival stratified by pCR (A), postoperative pathological node status (B), baseline EMVI status (C), baseline CRM status (D), and PD-L1 CPS (E). CI, confidence interval; CPS, combined positive score; CRM, circumferential resection margin; EMVI, extramural venous invasion; pCR, pathological complete response; PD-L1, programmed cell death-ligand 1

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us